NASDAQ:URGN

UroGen Pharma Competitors

$17.64
+0.16 (+0.92 %)
(As of 04/14/2021 03:59 PM ET)
Add
Compare
Today's Range
$17.59
Now: $17.64
$18.24
50-Day Range
$17.57
MA: $19.60
$23.35
52-Week Range
$17.01
Now: $17.64
$30.89
Volume5,322 shs
Average Volume207,576 shs
Market Capitalization$368.62 million
P/E RatioN/A
Dividend YieldN/A
Beta1.32

Competitors

UroGen Pharma (NASDAQ:URGN) Vs. IMGN, SAVA, AMTI, GBIO, ZEAL, and ATBPD

Should you be buying URGN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to UroGen Pharma, including ImmunoGen (IMGN), Cassava Sciences (SAVA), Applied Molecular Transport (AMTI), Generation Bio (GBIO), Zealand Pharma A/S (ZEAL), and Antibe Therapeutics (ATBPD).

UroGen Pharma (NASDAQ:URGN) and ImmunoGen (NASDAQ:IMGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Institutional & Insider Ownership

71.6% of UroGen Pharma shares are owned by institutional investors. Comparatively, 73.0% of ImmunoGen shares are owned by institutional investors. 12.0% of UroGen Pharma shares are owned by company insiders. Comparatively, 3.8% of ImmunoGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares UroGen Pharma and ImmunoGen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
UroGen Pharma$20,000.0018,431.15$-105,150,000.00($5.12)-3.45
ImmunoGen$82.27 million18.48$-104,130,000.00($0.70)-10.87

ImmunoGen has higher revenue and earnings than UroGen Pharma. ImmunoGen is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

UroGen Pharma has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Comparatively, ImmunoGen has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500.

Profitability

This table compares UroGen Pharma and ImmunoGen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
UroGen PharmaN/A-92.22%-81.71%
ImmunoGen-77.65%N/A-26.98%

Analyst Ratings

This is a breakdown of current recommendations and price targets for UroGen Pharma and ImmunoGen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
UroGen Pharma00303.00
ImmunoGen03402.57

UroGen Pharma presently has a consensus target price of $42.25, indicating a potential upside of 139.51%. ImmunoGen has a consensus target price of $10.10, indicating a potential upside of 32.72%. Given UroGen Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe UroGen Pharma is more favorable than ImmunoGen.

Summary

ImmunoGen beats UroGen Pharma on 8 of the 14 factors compared between the two stocks.

UroGen Pharma (NASDAQ:URGN) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Volatility & Risk

UroGen Pharma has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500.

Profitability

This table compares UroGen Pharma and Cassava Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
UroGen PharmaN/A-92.22%-81.71%
Cassava SciencesN/A-22.01%-20.85%

Insider and Institutional Ownership

71.6% of UroGen Pharma shares are owned by institutional investors. Comparatively, 26.7% of Cassava Sciences shares are owned by institutional investors. 12.0% of UroGen Pharma shares are owned by company insiders. Comparatively, 13.7% of Cassava Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares UroGen Pharma and Cassava Sciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
UroGen Pharma$20,000.0018,431.15$-105,150,000.00($5.12)-3.45
Cassava SciencesN/AN/A$-4,630,000.00($0.27)-132.00

Cassava Sciences has lower revenue, but higher earnings than UroGen Pharma. Cassava Sciences is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for UroGen Pharma and Cassava Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
UroGen Pharma00303.00
Cassava Sciences00403.00

UroGen Pharma presently has a consensus price target of $42.25, suggesting a potential upside of 139.51%. Cassava Sciences has a consensus price target of $35.3333, suggesting a potential downside of 0.86%. Given UroGen Pharma's higher probable upside, equities analysts plainly believe UroGen Pharma is more favorable than Cassava Sciences.

Summary

Cassava Sciences beats UroGen Pharma on 7 of the 11 factors compared between the two stocks.

Applied Molecular Transport (NASDAQ:AMTI) and UroGen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.

Institutional & Insider Ownership

52.0% of Applied Molecular Transport shares are held by institutional investors. Comparatively, 71.6% of UroGen Pharma shares are held by institutional investors. 12.0% of UroGen Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations for Applied Molecular Transport and UroGen Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Applied Molecular Transport00403.00
UroGen Pharma00303.00

Applied Molecular Transport presently has a consensus target price of $68.75, indicating a potential upside of 64.91%. UroGen Pharma has a consensus target price of $42.25, indicating a potential upside of 139.51%. Given UroGen Pharma's higher probable upside, analysts clearly believe UroGen Pharma is more favorable than Applied Molecular Transport.

Earnings & Valuation

This table compares Applied Molecular Transport and UroGen Pharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied Molecular TransportN/AN/A$-28,040,000.00N/AN/A
UroGen Pharma$20,000.0018,431.15$-105,150,000.00($5.12)-3.45

Applied Molecular Transport has higher earnings, but lower revenue than UroGen Pharma.

Profitability

This table compares Applied Molecular Transport and UroGen Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Applied Molecular TransportN/AN/AN/A
UroGen PharmaN/A-92.22%-81.71%

UroGen Pharma (NASDAQ:URGN) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for UroGen Pharma and Generation Bio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
UroGen Pharma00303.00
Generation Bio00603.00

UroGen Pharma currently has a consensus target price of $42.25, suggesting a potential upside of 139.51%. Generation Bio has a consensus target price of $40.60, suggesting a potential upside of 52.80%. Given UroGen Pharma's higher possible upside, equities analysts plainly believe UroGen Pharma is more favorable than Generation Bio.

Insider & Institutional Ownership

71.6% of UroGen Pharma shares are held by institutional investors. Comparatively, 63.3% of Generation Bio shares are held by institutional investors. 12.0% of UroGen Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares UroGen Pharma and Generation Bio's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
UroGen Pharma$20,000.0018,431.15$-105,150,000.00($5.12)-3.45
Generation BioN/AN/AN/AN/AN/A

Generation Bio has lower revenue, but higher earnings than UroGen Pharma.

Profitability

This table compares UroGen Pharma and Generation Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
UroGen PharmaN/A-92.22%-81.71%
Generation BioN/AN/AN/A

Summary

UroGen Pharma beats Generation Bio on 4 of the 7 factors compared between the two stocks.

Zealand Pharma A/S (NASDAQ:ZEAL) and UroGen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Insider and Institutional Ownership

4.3% of Zealand Pharma A/S shares are owned by institutional investors. Comparatively, 71.6% of UroGen Pharma shares are owned by institutional investors. 12.0% of UroGen Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Zealand Pharma A/S and UroGen Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zealand Pharma A/S-214.31%-38.34%-30.40%
UroGen PharmaN/A-92.22%-81.71%

Earnings & Valuation

This table compares Zealand Pharma A/S and UroGen Pharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zealand Pharma A/S$6.20 million222.32$-85,670,000.00($2.54)-12.50
UroGen Pharma$20,000.0018,431.15$-105,150,000.00($5.12)-3.45

Zealand Pharma A/S has higher revenue and earnings than UroGen Pharma. Zealand Pharma A/S is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Zealand Pharma A/S has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, UroGen Pharma has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Zealand Pharma A/S and UroGen Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zealand Pharma A/S00203.00
UroGen Pharma00303.00

Zealand Pharma A/S currently has a consensus price target of $43.00, indicating a potential upside of 35.39%. UroGen Pharma has a consensus price target of $42.25, indicating a potential upside of 139.51%. Given UroGen Pharma's higher possible upside, analysts clearly believe UroGen Pharma is more favorable than Zealand Pharma A/S.

Summary

UroGen Pharma beats Zealand Pharma A/S on 8 of the 13 factors compared between the two stocks.

UroGen Pharma (NASDAQ:URGN) and Antibe Therapeutics (NASDAQ:ATBPD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Earnings & Valuation

This table compares UroGen Pharma and Antibe Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
UroGen Pharma$20,000.0018,431.15$-105,150,000.00($5.12)-3.45
Antibe Therapeutics$7.51 million188.60$-14,540,000.00($0.50)-7.32

Antibe Therapeutics has higher revenue and earnings than UroGen Pharma. Antibe Therapeutics is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

UroGen Pharma has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, Antibe Therapeutics has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Institutional & Insider Ownership

71.6% of UroGen Pharma shares are held by institutional investors. 12.0% of UroGen Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares UroGen Pharma and Antibe Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
UroGen PharmaN/A-92.22%-81.71%
Antibe Therapeutics-273.96%-176.23%-106.91%

Analyst Recommendations

This is a breakdown of current ratings and price targets for UroGen Pharma and Antibe Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
UroGen Pharma00303.00
Antibe Therapeutics0000N/A

UroGen Pharma currently has a consensus price target of $42.25, suggesting a potential upside of 139.51%. Given UroGen Pharma's higher possible upside, research analysts plainly believe UroGen Pharma is more favorable than Antibe Therapeutics.

Summary

UroGen Pharma beats Antibe Therapeutics on 10 of the 13 factors compared between the two stocks.


UroGen Pharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.61+4.5%$1.45 billion$82.27 million-18.56News Coverage
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$35.64+1.1%$1.44 billionN/A-148.50Gap Down
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$41.69+2.4%$1.43 billionN/A0.00Gap Down
Generation Bio logo
GBIO
Generation Bio
1.8$26.57+4.4%$1.43 billionN/A0.00Insider Selling
Increase in Short Interest
News Coverage
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$31.76+3.2%$1.42 billion$6.20 million-13.93Gap Up
ATBPD
Antibe Therapeutics
0.1$3.66+0.0%$1.42 billion$7.51 million-6.10Gap Down
Endo International logo
ENDP
Endo International
1.3$6.27+2.6%$1.41 billion$2.91 billion-9.22News Coverage
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$27.95+0.5%$1.39 billionN/A-3.03Gap Down
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.55+3.7%$1.37 billion$19.89 million-13.47
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$27.85+5.0%$1.37 billion$4.23 million-20.63Increase in Short Interest
News Coverage
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$21.28+3.3%$1.34 billion$73.41 million-4.50Unusual Options Activity
News Coverage
Gap Down
Shattuck Labs logo
STTK
Shattuck Labs
1.5$32.90+2.4%$1.34 billionN/A0.00Analyst Report
Increase in Short Interest
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$35.71+1.8%$1.33 billionN/A0.00Analyst Upgrade
OLMA
Olema Pharmaceuticals
1.6$35.87+9.5%$1.30 billionN/A0.00Increase in Short Interest
Zymeworks logo
ZYME
Zymeworks
1.8$30.02+7.0%$1.29 billion$29.54 million-7.96News Coverage
Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$22.02+4.0%$1.28 billionN/A0.00Insider Selling
Unusual Options Activity
Gap Down
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$38.12+2.2%$1.22 billionN/A-2.73Gap Down
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$34.27+3.5%$1.21 billionN/A-19.04
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.46+3.5%$1.21 billion$4.23 million-9.20News Coverage
Gap Down
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$34.53+6.1%$1.20 billionN/A0.00
Innoviva logo
INVA
Innoviva
1.4$11.75+1.0%$1.18 billion$261.02 million5.99
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$25.14+20.8%$1.17 billionN/A0.00Increase in Short Interest
Lockup Expiration
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.22+0.1%$1.17 billion$59.70 million-192.20
NKTX
Nkarta
1.8$35.83+0.8%$1.17 billionN/A0.00Increase in Short Interest
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.13+1.7%$1.13 billion$35.22 million-7.39
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$25.89+1.2%$1.12 billion$230,000.00-12.04News Coverage
Gap Down
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$17.15+5.8%$1.12 billion$42.12 million-12.70Unusual Options Activity
News Coverage
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.71+4.2%$1.11 billionN/A-8.99Increase in Short Interest
Omeros logo
OMER
Omeros
1.4$17.51+0.1%$1.08 billion$111.81 million-7.36
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$30.14+0.4%$1.08 billion$57.05 million0.00
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$16.20+3.1%$1.07 billionN/A-6.84
Zogenix logo
ZGNX
Zogenix
1.7$19.41+1.6%$1.06 billion$3.65 million-2.04
MannKind logo
MNKD
MannKind
1.4$4.56+7.7%$1.05 billion$63.04 million-21.71Increase in Short Interest
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$23.01+4.9%$1.05 billionN/A-8.49Gap Down
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$10.23+1.5%$1.04 billion$120,000.00-3.79Analyst Upgrade
News Coverage
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$39.85+1.0%$1.04 billion$20.79 million-13.74Analyst Upgrade
News Coverage
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$20.71+0.3%$1.04 billionN/A-6.81Increase in Short Interest
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$24.77+2.0%$1.02 billionN/A-8.54
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$50.71+2.6%$996.70 million$122.47 million-27.86Analyst Downgrade
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$21.73+5.2%$993.66 million$1.52 million-11.56Increase in Short Interest
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.33+0.2%$982.60 million$800.40 million22.95
Prothena logo
PRTA
Prothena
2.1$23.94+2.4%$934.94 million$810,000.00-9.35Increase in Short Interest
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.27+3.2%$918.28 millionN/A-12.57Analyst Upgrade
ESSA Pharma logo
EPIX
ESSA Pharma
1.4$26.51+2.2%$914.76 millionN/A-24.55
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.44+0.8%$895.14 million$227.19 million45.67
Radius Health logo
RDUS
Radius Health
1.3$19.61+3.6%$886.30 million$173.32 million-8.04Gap Down
Annexon logo
ANNX
Annexon
1.9$23.23+0.8%$879.54 millionN/A0.00Increase in Short Interest
Gap Down
Affimed logo
AFMD
Affimed
1.6$10.33+4.3%$873.54 million$23.96 million-17.51Analyst Report
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$17.15+1.5%$869.64 millionN/A0.00News Coverage
Gap Down
Merus logo
MRUS
Merus
1.6$23.03+1.7%$863.20 million$31.13 million-7.50Analyst Report
Analyst Revision
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.